Lycia Therapeutics

Lycia Therapeutics is a clinical-stage biotechnology company pioneering extracellular protein degradation through its proprietary LYTAC (lysosomal targeting chimeras) platform, co-founded in 2019 with Nobel Laureate Carolyn Bertozzi. The company develops first-in-class degrader therapeutics targeting disease-causing proteins that circulate in blood or reside on cell surfaces — proteins previously considered undruggable. Its initial pipeline focuses on autoimmune and inflammatory diseases, including food allergy and Graves' disease, with LYTAC degraders designed to rapidly and selectively reduce pathogenic protein levels. With over $251M raised from investors including Eli Lilly, OrbiMed, and Janus Henderson, Lycia is advancing its lead programs toward clinical development.